The Challenge of Large Genes in Gene Therapy

Usher syndrome type 1B (USH1B) is caused by mutations in the MYO7A gene, which provides instructions for making myosin VIIA, a protein essential for the development and maintenance of hair cells in the inner ear and photoreceptors in the retina. A significant hurdle in developing gene therapies for USH1B has been the size of the MYO7A gene. Traditional gene therapy relies on adeno-associated virus (AAV) vectors to deliver healthy copies of a gene into target cells. However, the MYO7A gene is too large to fit into a single standard AAV container.

The Dual-Vector Solution

To overcome this capacity limit, researchers have developed an innovative dual-vector delivery system. This approach involves splitting the large MYO7A gene into two halves, packaging each half into a separate AAV vector. When both vectors are delivered to the same cell, the two halves recombine to form a complete, functional gene. This allows the cell to produce the full-length myosin VIIA protein.

Moving into Clinical Trials

This dual-vector strategy has recently transitioned from preclinical models to human clinical trials. A Phase 1/2 clinical trial, known as LUCE-1, has dosed its first patient to evaluate the safety and efficacy of this retinal gene therapy (AAVB-081) for individuals with USH1B. The trial involves a one-time treatment administered via a subretinal injection.

Key aspects of the trial include:
* Patient Population: Enrolling adults aged 18 to 50 with confirmed USH1B.
* Dose Evaluation: Testing three different dose levels to determine the optimal balance of safety and potential benefit.
* Primary Goals: Assessing the safety of the dual-vector approach and monitoring for any improvements or stabilization in visual function.

Future Implications

The success of the dual-vector approach could have far-reaching implications beyond USH1B. Other forms of Usher syndrome, such as USH1F (caused by mutations in the large PCDH15 gene) and USH2A, also face similar delivery challenges due to gene size. If the dual-vector system proves safe and effective, it could pave the way for a new generation of gene therapies for various inherited retinal diseases.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.